ABSTRACT
Importance Determining the SARS-CoV-2 infection rate in children is important for decisions about protective measures for the 2021–2022 school year.
Objective To estimate the prevalence of SARS-CoV-2 antibodies in serum samples from pediatric patients in the state of Arkansas as an indicator of SARS-CoV-2 infection.
Design The study is a survey of SARS-CoV-2 seropositivity in children in Arkansas over the first year of the COVID-19 pandemic. From April 2020 through April 2021, remnant serum samples were collected across five time periods (waves): April 2–May 6, June 6–August 10, September 8–October 17, November 7–December 17, 2020 and April 5–April 28, 2021.
Setting The multi-site survey collected remnant serum samples from four clinics in Arkansas.
Participants The study population consisted of 2400 convenience serum samples from children ages 1–18 who visited hospitals or regional clinics in Arkansas for non-COVID19-related reasons.
Exposures Infection with SARS-CoV-2.
Main outcomes and measures The presence of IgM and/or IgG antibodies to the SARS-CoV-2 Spike and Nucleoprotein were determined using a two-step ELISA. Seroprevalence was estimated by demographic group, including age, sex, race/ethnicity, metropolitan status, SARS-CoV-2 PCR testing, and co-morbidities. Association with SARS-CoV-2 antibody reactivity was determined by demographic group.
Results SARS-CoV-2 seroprevalence rose from 7.9% in Wave 1 (95%CI, 4.9-10.9%) to 25.8% in Wave 5 (95% CI, 22.2-29.3%). Hispanic children had a significantly higher risk of having antibodies than non-Hispanic white children in Wave 3 (RR 2.82, 95% CI, 1.81-4.38), Wave 4 (RR 1.76, 95% CI, 1.03-3.00), and Wave 5 (RR 2.37, 95% CI, 1.69-3.33) Similarly, black children also showed a significantly higher risk of having antibodies than white children in Wave 3 (RR 1.71, 95% CI, 1.03-2.84) and Wave 5 (RR 1.59, 95% CI, 1.08-2.34).
Conclusions and relevance Our data indicate that more children have been infected with SARS-CoV-2 than indicated by diagnostic testing. With the emergence of SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these results highlight the importance of including children in SARS-CoV-2 public health, clinical care, and research strategies. These findings are important for state and local officials as they consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021–2022 school year.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by funds from the state of Arkansas through the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive COVID-10 Research Award Program, the UAMS Translational Research Institute (UL1TR000039, TL1TR003109, and UL1TR003107), and the Center for Microbial Pathogenesis and Host Inflammatory Response (P20 GM103625).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All human specimens were obtained with oversight from the UAMS Institutional Review Board (IRB), and waiver of consent and HIPAA applied. The IRB number for the study is 261208.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos